Exercise and diet modestly improve QoL and fatigue on ADT

Editor's Pick: An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial (The Lancet Oncology, 2026)
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning targeted therapy in thoracic cancers, precision-guided treatment selection across molecularly defined groups, and next-generation antibody and cell therapies — plus one trial that finally tells us how to deliver exercise to men on hormone therapy. Let's dive in.
This week's papers:
• Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42685317)
• Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer. — Cancer Discovery 2026 (pubmed.ncbi.nlm.nih.gov/42689323)
• Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. — The Lancet 2026 (pubmed.ncbi.nlm.nih.gov/42702214)
• The changing therapeutic landscape of small-cell lung cancer. — The Lancet 2026 (pubmed.ncbi.nlm.nih.gov/42702213)
• Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42691436)
• Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42705255)
• Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42705254)
• Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42690668)
• Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42690647)
• An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42697217)
Listen at AudioScholar (audioscholar.cc/episode/th6q99xcfv)